- Home
- VIR vs UTZ Comparison
VIR vs UTZ Comparison
Compare VIR & UTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- UTZ
- Stock Information
- Founded
- VIR 2016
- UTZ 2018
- Country
- VIR United States
- UTZ United States
- Employees
- VIR N/A
- UTZ N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- UTZ Packaged Foods
- Sector
- VIR Health Care
- UTZ Consumer Staples
- Exchange
- VIR Nasdaq
- UTZ Nasdaq
- Market Cap
- VIR 844.9M
- UTZ N/A
- IPO Year
- VIR 2019
- UTZ N/A
- Fundamental
- Price
- VIR $5.41
- UTZ $12.35
- Analyst Decision
- VIR Strong Buy
- UTZ Buy
- Analyst Count
- VIR 7
- UTZ 9
- Target Price
- VIR $33.57
- UTZ $18.39
- AVG Volume (30 Days)
- VIR 1.0M
- UTZ 1.6M
- Earning Date
- VIR 05-07-2025
- UTZ 05-01-2025
- Dividend Yield
- VIR N/A
- UTZ 2.30%
- EPS Growth
- VIR N/A
- UTZ N/A
- EPS
- VIR N/A
- UTZ 0.32
- Revenue
- VIR $20,861,000.00
- UTZ $1,414,842,000.00
- Revenue This Year
- VIR N/A
- UTZ $2.46
- Revenue Next Year
- VIR $10.65
- UTZ $2.84
- P/E Ratio
- VIR N/A
- UTZ $37.99
- Revenue Growth
- VIR N/A
- UTZ N/A
- 52 Week Low
- VIR $4.95
- UTZ $11.53
- 52 Week High
- VIR $14.45
- UTZ $19.01
- Technical
- Relative Strength Index (RSI)
- VIR 35.98
- UTZ 41.13
- Support Level
- VIR $5.83
- UTZ $11.53
- Resistance Level
- VIR $6.29
- UTZ $13.52
- Average True Range (ATR)
- VIR 0.31
- UTZ 0.49
- MACD
- VIR 0.02
- UTZ -0.12
- Stochastic Oscillator
- VIR 28.80
- UTZ 34.89
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.